rna helicase-a

YK 4-279, an inhibitor of RNA Helicase A (RHA), binds to the oncogenic transciption factor EWS-FLI1.

CMLD012073 is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. It inhibits NIH 3T3 cells (IC50: 10 nM). CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A).

Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent, inducing cell apoptosis and inhibiting the growth of TNBC cancer cell lines (IC50s: 10 nM - 20 nM).

GBM CSCs-IN-1 (Compound (−)-20), a rocaglate derivative, potently inhibits glioblastoma stem cells (GBM CSCs) and exhibits an EC50 of 45 nM by targeting the RNA helicase DDX3. Additionally, it induces apoptosis in these cells.

SARS-CoV-2 nsp13-IN-7 (Compound 6r) is an inhibitor of SARS-CoV-2 nsp13, with an IC50 of 0.28 μM. This compound disrupts the helicase function of nsp13 by binding to its 5' RNA site and ATP binding site, and it serves as a lead compound for developing antiviral drugs targeting SARS-CoV-2 nsp13.

Brr2-IN-3 (Brr2 Inhibitor C9) is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa (a group of progressive retinal degenerative disorders).

RK33 (RK 33) is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.

DHX9-IN-2 is an inhibitor targeting ATP-dependent RNA de-helicase A (DHX9) with anticancer and antitumor activity for cancer research.

DHX9-IN-1 is a potent ATP-dependent RNA helicase A (DHX9) inhibitor, exhibiting an IC50 of 9.45 nM and demonstrating antitumor activity [1].

DHX9-IN-13 (389) serves as an inhibitor of the RNA helicase DHX9, demonstrating a cellular target engagement EC50 of 3.4 μM. It is primarily utilized in cancer research [1].

DHX9-IN-17 (186) serves as an inhibitor of the RNA helicase DHX9, demonstrating a target engagement EC50 value of 0.161 μM in cellular assays. It is utilized in cancer research [1].

DHX9-IN-3 (Compound 621) acts as an ATP-dependent inhibitor of RNA helicase A (DHX9), and holds potential for use in cancer research [1].

DHX9-IN-6 is a highly effective ATP-dependent RNA helicase A (DHX9) inhibitor, used in cancer research.

DHX9-IN-7 (550) acts as an inhibitor of the RNA helicase DHX9, displaying a potent EC 50 value of 0.105 μM for cellular target engagement. It is frequently utilized in cancer research [1].

Fli-1-IN-1 (compound 21) serves as a FLI1 inhibitor by binding directly to the EWS-FLI1 protein, disrupting its interaction with RNA helicase A. This inhibition holds potential anticancer properties [1].